Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 52Other hematologic neoplasm 27Dermatologic 2CNS 2Myeloid 1Classical hematology 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Cyclophosphamide 8Whole-Body Irradiation 6fludarabine 5fludarabine phosphate 4Tacrolimus 4Mycophenolic Acid 4Melphalan 4Busulfan 3luspatercept 2Vorinostat 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Biopsy 2Azacitidine 2AP 1903 reagent 2venetoclax 1ribociclib 1palbociclib 1olaparib 1ibrutinib 1hetrombopag 1edoxaban 1decitabine and cedazuridine drug combination 1apixaban 1acalabrutinib 1abemaciclib 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × ibrutinib × Classical hematology × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡